Andreas Jung

The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial

C. Giessen, C. Schulz, M. Haas, 2012, International journal of cancer.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

A. Kiani, S. Al-Batran, T. Kirchner, 2017, European journal of cancer.

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

C. Berking, A. Gesierich, M. Heppt, 2017, BMC Cancer.

LEF‐1 expression in basal cell carcinomas

Lydia Kriegl, Andreas Jung, Thomas Kirchner, 2009, The British journal of dermatology.

KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer

V. Heinemann, A. Jung, R. Laubender, 2013, Journal of Cancer Research and Clinical Oncology.

The Treatment of Colorectal Carcinoma With Monoclonal Antibodies

W. Hiddemann, V. Heinemann, T. Kirchner, 2009 .